Study Description: This study is being done to help find out if niraparib, the study drug, can help delay worsening of cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug.
Eligibility Criteria: Patients must be able to understand the study procedures and agree to particpate in the study by providing written informed consent.
Patients must be female at leaset 18 years of age.
Patients must agree to undergo Homologus Recombination Deficiency (HRD) testing.
Patients must not be pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 3 months after the last dose of study treatment.
Please see the protocol for a complete list of the eligibility criteria.
Compensation: No, subjects will not be compensated.